Vanta Holdings Expands into U.S. Peptide Market with Strategic Agreement

Vanta Holdings Inc. has signed a strategic agreement to enter the U.S. peptide therapy market, focusing on telehealth-enabled commercialization. The company will leverage FDA-registered compounding pharmacy relationships, a compliant payment infrastructure, and scalable fulfillment capabilities. This move is part of Vanta's strategy to create a consumer health sciences platform targeting wellness and longevity.

The U.S. peptide therapy platform aims to be an integrated ecosystem supporting patient acquisition, clinician consultations, and subscription-based revenue. It will offer peptide therapy, nutraceuticals, and hydration products, tapping into rising demand for preventative health and wellness solutions.

Vanta projects the U.S. peptide therapeutics market could exceed $160 billion by 2030, driven by personalized medicine and performance optimization. The agreement sets up Vanta for long-term growth in the rapidly emerging longevity economy, expected to reach $1.4 trillion by 2029.